Zhejiang Medicine: Intends to subscribe for private equity fund shares worth 157 million yuan.

Zhejiang Pharmaceutical announced that on March 9, 2026, the company signed a "Partnership Agreement" with Xiamen Huaxun Contemporary Entrepreneurship Investment Management Co., Ltd., jointly investing in Xiamen Huaxun Qiuhang Equity Investment Partnership Enterprise. The total subscribed capital of the partnership enterprise is 320 million yuan, with the company subscribing 157 million yuan with its own funds, accounting for 49.06%. The fund mainly focuses on strategic emerging industries such as biopharmaceuticals, with investments not less than 60% of the fund size. This transaction does not constitute a related party transaction or major asset restructuring, and still needs to go through the fund filing procedures. There are risks of not achieving expected returns or loss of principal in the investment.